BACKGROUND: African American (AA) men in the general US population are more than twice as likely to die of prostate cancer (PC) compared with non-Hispanic white (NHW) men. The authors hypothesized that receiving care through the Veterans Affairs (VA) health system, an equal-access medical system, would attenuate this disparity. METHODS: A longitudinal, centralized database of >20 million veterans was used to assemble a cohort of 60,035 men (18,201 AA men [30.3%] and 41,834 NHW men [69.7%]) who were diagnosed with PC between 2000 and 2015. RESULTS: AA men were more likely to live in regions with a lower median income ($40,871 for AA men vs $48,125 for NHW men; P < .001) and lower high school graduation rates (83% for AA men vs 88% for NHW men; P < .001). At the time of diagnosis, AA men were younger (median age, 63.0 years vs 66.0 years; P < .001) and had a higher prostate-specific antigen level (median, 6.7 ng/mL vs 6.2 ng/mL; P < .001), but were less likely to have Gleason score 8 to 10 disease (18.8% among AA men vs 19.7% among NHW men; P < .001), a clinical T classification ≥3 (2.2% vs 2.9%; P < .001), or distant metastatic disease (2.7% vs 3.1%; P = 0.01). The 10-year PC-specific mortality rate was slightly lower for AA men (4.4% vs 5.1%; P = .005), which was confirmed in multivariable competing-risk analysis (subdistribution hazard ratio, 0.85; 95% CI, 0.78-0.93; P < .001). CONCLUSIONS: AA men diagnosed with PC in the VA health system do not appear to present with more advanced disease or experience worse outcomes compared with NHW men, in contrast to national trends, suggesting that access to care is an important determinant of racial equity.
BACKGROUND: African American (AA) men in the general US population are more than twice as likely to die of prostate cancer (PC) compared with non-Hispanic white (NHW) men. The authors hypothesized that receiving care through the Veterans Affairs (VA) health system, an equal-access medical system, would attenuate this disparity. METHODS: A longitudinal, centralized database of >20 million veterans was used to assemble a cohort of 60,035 men (18,201 AA men [30.3%] and 41,834 NHW men [69.7%]) who were diagnosed with PC between 2000 and 2015. RESULTS: AA men were more likely to live in regions with a lower median income ($40,871 for AA men vs $48,125 for NHW men; P < .001) and lower high school graduation rates (83% for AA men vs 88% for NHW men; P < .001). At the time of diagnosis, AA men were younger (median age, 63.0 years vs 66.0 years; P < .001) and had a higher prostate-specific antigen level (median, 6.7 ng/mL vs 6.2 ng/mL; P < .001), but were less likely to have Gleason score 8 to 10 disease (18.8% among AA men vs 19.7% among NHW men; P < .001), a clinical T classification ≥3 (2.2% vs 2.9%; P < .001), or distant metastatic disease (2.7% vs 3.1%; P = 0.01). The 10-year PC-specific mortality rate was slightly lower for AA men (4.4% vs 5.1%; P = .005), which was confirmed in multivariable competing-risk analysis (subdistribution hazard ratio, 0.85; 95% CI, 0.78-0.93; P < .001). CONCLUSIONS: AA men diagnosed with PC in the VA health system do not appear to present with more advanced disease or experience worse outcomes compared with NHW men, in contrast to national trends, suggesting that access to care is an important determinant of racial equity.
Authors: Stephanie Navarro; Xiaohui Hu; Aaron Mejia; Carol Y Ochoa; Trevor A Pickering; Leslie Ballas; Albert J Farias Journal: Cancer Causes Control Date: 2022-01-15 Impact factor: 2.506
Authors: Jonathan Pastrana Del Valle; Nathanael R Fillmore; George Molina; Mark Fairweather; Jiping Wang; Thomas E Clancy; Stanley W Ashley; Richard D Urman; Edward E Whang; Jason S Gold Journal: Ann Surg Oncol Date: 2022-01-10 Impact factor: 5.344
Authors: Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano Journal: Cancer Health Disparities Date: 2020
Authors: Morgan L Zenner; Yves B Helou; Ryan J Deaton; Maria Sverdlov; Heng Wang; Andre Kajdacsy-Balla; Virgilia Macias; Cindy Voisine; Marcus Murray; Sarki A Abdulkadir; Adam B Murphy; Larisa Nonn Journal: Prostate Date: 2021-12-02 Impact factor: 4.104
Authors: Nishwant Swami; Yefri A Baez; Idalid Franco; Tiffany Nguyen; Karthik Meiyappan; Minh Ton; Bhav Jain; Crystal Seldon; Kenrick Ng; Narjust Duma; Mohammed Alshalalfa; Kosj Yamoah; Paul L Nguyen; Brandon A Mahal; Edward Christopher Dee Journal: Prostate Cancer Prostatic Dis Date: 2022-03-19 Impact factor: 5.554
Authors: Sirpi Nackeeran; Isaac Zucker; Iakov Efimenko; Alexander Weber; Scott C Brown; Ranjith Ramasamy; Thomas Masterson Journal: Int J Impot Res Date: 2022-09-23 Impact factor: 2.408
Authors: Spyridon P Basourakos; Roman Gulati; Randy A Vince; Daniel E Spratt; Patrick J Lewicki; Alexander Hill; Yaw A Nyame; Jennifer Cullen; Sarah C Markt; Christopher E Barbieri; Jim C Hu; Erika Trapl; Jonathan E Shoag Journal: NEJM Evid Date: 2022-05-15
Authors: Daniella Klebaner; P Travis Courtney; Isla P Garraway; John Einck; Abhishek Kumar; Maria Elena Martinez; Rana McKay; James D Murphy; Humberto Parada; Ajay Sandhu; Tyler Stewart; Kosj Yamoah; Brent S Rose Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 11.816